Emergent BioSolutions Inc (EBS)
2.04
+0.18
(+9.68%)
USD |
NYSE |
Apr 19, 16:00
2.06
+0.02
(+0.98%)
After-Hours: 20:00
Emergent BioSolutions Enterprise Value: 845.60M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 845.60M |
| April 17, 2024 | 847.69M |
| April 16, 2024 | 850.30M |
| April 15, 2024 | 851.86M |
| April 12, 2024 | 856.04M |
| April 11, 2024 | 862.83M |
| April 10, 2024 | 864.91M |
| April 09, 2024 | 869.09M |
| April 08, 2024 | 869.61M |
| April 05, 2024 | 868.05M |
| April 04, 2024 | 867.00M |
| April 03, 2024 | 866.48M |
| April 02, 2024 | 861.26M |
| April 01, 2024 | 868.57M |
| March 28, 2024 | 880.57M |
| March 27, 2024 | 883.71M |
| March 26, 2024 | 875.88M |
| March 25, 2024 | 881.10M |
| March 22, 2024 | 874.31M |
| March 21, 2024 | 877.44M |
| March 20, 2024 | 879.53M |
| March 19, 2024 | 876.92M |
| March 18, 2024 | 877.44M |
| March 15, 2024 | 876.40M |
| March 14, 2024 | 871.18M |
| Date | Value |
|---|---|
| March 13, 2024 | 865.44M |
| March 12, 2024 | 870.13M |
| March 11, 2024 | 894.67M |
| March 08, 2024 | 888.93M |
| March 07, 2024 | 893.10M |
| March 06, 2024 | 918.68M |
| March 05, 2024 | 926.51M |
| March 04, 2024 | 913.98M |
| March 01, 2024 | 925.47M |
| February 29, 2024 | 917.12M |
| February 28, 2024 | 915.55M |
| February 27, 2024 | 920.76M |
| February 26, 2024 | 897.27M |
| February 23, 2024 | 891.53M |
| February 22, 2024 | 894.66M |
| February 21, 2024 | 889.96M |
| February 20, 2024 | 827.84M |
| February 16, 2024 | 829.93M |
| February 15, 2024 | 837.24M |
| February 14, 2024 | 836.72M |
| February 13, 2024 | 831.50M |
| February 12, 2024 | 842.46M |
| February 09, 2024 | 830.98M |
| February 08, 2024 | 836.20M |
| February 07, 2024 | 826.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
826.80M
Minimum
Feb 07 2024
7.660B
Maximum
Aug 13 2020
2.927B
Average
2.872B
Median
Enterprise Value Benchmarks
| Avid Bioservices Inc | 522.68M |
| Viking Therapeutics Inc | 6.143B |
| FibroGen Inc | -7.110M |
| Avinger Inc | 15.69M |
| RAPT Therapeutics Inc | 117.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.50M |
| Revenue (Quarterly) | 269.90M |
| Total Expenses (Quarterly) | 313.70M |
| EPS Diluted (Quarterly) | -0.88 |
| Gross Profit Margin (Quarterly) | 31.42% |
| Profit Margin (Quarterly) | -18.34% |
| Earnings Yield | -723.5% |
| Normalized Earnings Yield | -341.40 |